Predictive Power of Baseline [18F]FDG PET/CT for Adverse Events in DLBCL Patients Undergoing CAR-T Cell Therapy
Authors:
- Helena A. PetersHPHelena A. Peters
- Emil NovruzovEmil Novruzov
- Ben-Niklas BärmannBBBen-Niklas Bärmann
- Daniel WeissDWDaniel Weiss
- Matthias BoschheidgenMBMatthias Boschheidgen
- Vivien Lorena IvanVIVivien Lorena Ivan
- Nora LiebersNLNora Liebers
- Johannes FischerJFJohannes Fischer
- Eduards MamlinsEMEduards Mamlins
- Aleksandar RadujkovicARAleksandar Radujkovic
- Guido KobbeGKGuido Kobbe
- Julian KirchnerJKJulian Kirchner
Open Access
- 13 August 2025
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 15 (16) , 2025
Abstract
Objectives: Evaluation of the predictive potential of pre-CAR-T [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma (DLBCL) patients concerning Cytokine Release Syndrome (CRS) and Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS). Methods: Eighteen DLBCL patients (mean age: 60 ± 12 years) who underwent pre-therapeutic [18F]FDG-PET/CT and CAR-T cell therapy were retrospectively included. Median follow-up time was ten months (IQR6-16) after CAR-T cell infusion. Age, sex, serum lactate dehydrogenase (LDH), interleukin-6 (IL-6), C-reactive protein (CRP), and modified Endothelial Activation and Stress Index (mEASIX) were obtained. Potential occurrence of CRS/ICANS and the SUVmax were evaluated. Pearson and Spearman correlations, group comparisons (Mann–Whitney U-test) and the odds ratio (OR) were calculated. P values below 0.05 were defined as statistically significant and 95%-confidence intervals (CI) were calculated. Results: Pre-therapeutic SUVmax correlated positively with LDH (r = 0.5; p = 0.02), with the grade of CRS (r = 0.5; p = 0.03) and with the grade of ICANS (r = 0.6; p = 0.01). Appearance of ICANS was significantly correlated with pre-therapeutic SUVmax (p = 0.03; U = 7.0; Z = −2.2). Using ROC analysis and Youden’s index, an SUVmax threshold of 17 (AUC: 0.865; p < 0.01) was defined. Patients exceeding a pre-therapeutic SUVmax of 17 had a significantly higher risk of CRS grade > 1 (OR = 22; CI 2, 314; p = 0.03) and ICANS grade > 1 (OR = 18; CI 1, 271; p = 0.04). Conclusions: Pre-therapeutic SUVmax may be a useful marker for identifying DLBCL patients at risk for CRS and ICANS.Keywords
This publication has 34 references indexed in Scilit:
- Latest updates on pathogenesis mechanisms and management strategies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis related to CAR-T cell therapiesAnnals of Hematology, 2025
- Personalised PET imaging in oncology: an umbrella review of meta-analyses to guide the appropriate radiopharmaceutical choice and indicationEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- [18F]FDG PET/CT for prognosis and toxicity prediction of diffuse large B-cell lymphoma patients with chimeric antigen receptor T-cell therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- Metabolic parameters predict survival and toxicity in chimeric antigen receptor T‐cell therapy‐treated relapsed/refractory large B‐cell lymphomaHematological Oncology, 2023
- Baseline [18F]FDG PET features are associated with survival and toxicity in patients treated with CAR T cells for large B cell lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2023
- CAR T-cell therapy and critical careWiener klinische Wochenschrift, 2021
- 18F-FDG PET/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphomaAnnals of Nuclear Medicine, 2020
- Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin LymphomaTransplantation and Cellular Therapy, 2019
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- World Medical Association Declaration of HelsinkiJAMA, 2013